-
公开(公告)号：US20100210731A1
公开(公告)日：2010-08-19
申请号：US12708998
申请日：2010-02-19
IPC分类号： A61K31/165 , C07C233/11 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： C07C317/50 , A61K31/165 , C07C317/44
摘要： Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
摘要翻译： 形成和讨论了外消旋，对映异构体纯和对映体混合的莫达非尼的多晶型物和溶剂合物。 此外，所述形式被描述为可用于治疗许多病症，包括但不限于发作性睡病。
-
公开(公告)号：US07566805B2
公开(公告)日：2009-07-28
申请号：US10570405
申请日：2004-09-04
IPC分类号： C07C323/22 , A61K31/165
CPC分类号： C07C317/38
摘要： Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.
摘要翻译： 形成外消旋，对映异构体纯和对映异构体混合的莫达非尼的共晶体和溶剂合物，并调制几种重要的物理性质。 可以调节莫达非尼的溶解度，溶解度，生物利用度，剂量反应和稳定性，以提高药物组合物的功效。
-
公开(公告)号：US07763112B2
公开(公告)日：2010-07-27
申请号：US11413353
申请日：2006-04-28
IPC分类号： C30B7/02
CPC分类号： B02C17/20 , B01F11/0005 , B01F13/005 , B01F13/0052 , B01J2219/00313 , B01J2219/00484 , B01J2219/00756 , B01L3/06 , B02C17/14 , B02C17/1815 , B02C2017/065 , C30B7/00 , C30B29/54
摘要： The present invention comprises methods and apparatuses for the production or formation of co-crystals. The methods and apparatuses can be used to grind two or more co-crystal components resulting in the formation of co-crystals. The resultant co-crystals can have several uses as disclosed herein.
摘要翻译： 本发明包括用于生产或形成共晶体的方法和装置。 该方法和装置可用于研磨两种或多种共晶体组分，从而形成共晶体。 所得的共晶体可以具有本文公开的多种用途。
-
公开(公告)号：US07671093B2
公开(公告)日：2010-03-02
申请号：US11139245
申请日：2005-05-27
IPC分类号： A61K31/165
CPC分类号： A61K31/165 , A61K9/145 , A61K31/191 , C07C55/10 , C07C57/15 , C07C317/44 , A61K2300/00
摘要： A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.
摘要翻译： 描述了包含API，第一共晶体形成器和与所述第一共晶体形成体同构取代的第二共晶体形成器的混合共晶体。 还描述了包含混合共晶的药物组合物，制备混合共晶体的方法和使用混合共晶体的方法。
-
公开(公告)号：US20060287392A1
公开(公告)日：2006-12-21
申请号：US11461830
申请日：2006-08-02
申请人： Matthew Peterson , Mark Oliveira
发明人： Matthew Peterson , Mark Oliveira
IPC分类号： A61K31/195 , C07C229/28 , C07C275/02
CPC分类号： C07C59/255 , C07C57/145
摘要： The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.
摘要翻译： 本发明包括加巴喷丁的有机酸盐，其中有机酸是酒石酸，乙二磺酸或马来酸。 讨论了调节加巴喷丁的溶解度和剂量反应的方法。 还讨论了加巴喷丁的有机酸盐的制备方法。
-
公开(公告)号：US20060052432A1
公开(公告)日：2006-03-09
申请号：US10528244
申请日：2003-09-16
申请人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
发明人： Julius Remenar , Matthew Peterson , Orn Almarsson , Hector Guzman , Hongming Chen , Mark Tawa , Mark Oliveira
IPC分类号： A61K9/00 , A61K31/18 , A61K31/415 , A61K31/365
CPC分类号： A61K9/0019 , A61K9/145 , A61K9/146 , A61K31/18 , A61K31/365 , A61K31/415 , A61K31/635 , A61K47/10
摘要： The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.
-
公开(公告)号：US20050267209A1
公开(公告)日：2005-12-01
申请号：US11139245
申请日：2005-05-27
IPC分类号： A01N37/18 , A61K9/00 , A61K9/20 , A61K9/26 , A61K31/165 , A61K31/191 , A61K31/205
CPC分类号： A61K31/165 , A61K9/145 , A61K31/191 , C07C55/10 , C07C57/15 , C07C317/44 , A61K2300/00
摘要： A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.
摘要翻译： 描述了包含API，第一共晶体形成器和与所述第一共晶体形成器同构取代的第二共晶体形成器的混合共晶体。 还描述了包含混合共晶的药物组合物，制备混合共晶体的方法和使用混合共晶体的方法。
-
8.发明申请Novel Isovaleramide Forms, Compositions Thereof, and Related Methods of Use 审中-公开新型异戊酰胺形式，组合物及相关使用方法公开(公告)号：US20080287542A1
公开(公告)日：2008-11-20
申请号：US11912759
申请日：2006-04-27
申请人： Mark Oliveira , Matthew Peterson
发明人： Mark Oliveira , Matthew Peterson
IPC分类号： A61K31/195 , A61P25/24 , A61P25/18 , A61P25/00
CPC分类号： C07C233/05 , C07C59/265
摘要： The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety.
摘要翻译： 本发明提供新的异戊酰胺形式。 这些形式包括异戊酰胺共晶体，溶剂合物，水合物，共晶体及其多晶型物。 本发明还提供了包含这些新颖形式和一种或多种合适载体的新型组合物。 本发明还提供相关的治疗或预防方法。 本发明的组合物和方法具有许多用途，包括治疗或预防癫痫和焦虑。
-
公开(公告)号：US20070021510A1
公开(公告)日：2007-01-25
申请号：US10570405
申请日：2004-09-04
申请人： Magali Hickey , Matthew Peterson , Orn Almarsson , Mark Oliveira
发明人： Magali Hickey , Matthew Peterson , Orn Almarsson , Mark Oliveira
IPC分类号： A61K31/165
CPC分类号： C07C317/38
摘要： Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.
摘要翻译： 形成外消旋，对映异构体纯和对映异构体混合的莫达非尼的共晶体和溶剂合物，并调制几种重要的物理性质。 可以调节莫达非尼的溶解度，溶解度，生物利用度，剂量反应和稳定性，以提高药物组合物的功效。
-
公开(公告)号：US20060243831A1
公开(公告)日：2006-11-02
申请号：US11413353
申请日：2006-04-28
IPC分类号： B02C17/00
CPC分类号： B02C17/20 , B01F11/0005 , B01F13/005 , B01F13/0052 , B01J2219/00313 , B01J2219/00484 , B01J2219/00756 , B01L3/06 , B02C17/14 , B02C17/1815 , B02C2017/065 , C30B7/00 , C30B29/54
摘要： The present invention comprises methods and apparatuses for the production or formation of co-crystals. The methods and apparatuses can be used to grind two or more co-crystal components resulting in the formation of co-crystals. The resultant co-crystals can have several uses as disclosed herein.
摘要翻译： 本发明包括用于生产或形成共晶体的方法和装置。 该方法和装置可用于研磨两种或多种共晶体组分，从而形成共晶体。 所得的共晶体可以具有本文公开的多种用途。
-
-
-
-
-
-
-
-
-
搜索结果
82 条记录 (耗时 0.03 秒)
